---
title: "Werewolf Therapeutics (HOWL) stock and investor profile"
url: "https://aibio.space/companies/werewolf-therapeutics/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "Werewolf Therapeutics, Inc. (NASDAQ: HOWL), United States. The directory classifies it as Pharmaceuticals: Major."
---

HOWL Werewolf Therapeutics, Inc. NASDAQ · United States

# Werewolf Therapeutics (HOWL) news

Distress · 2026-02-13

## [Werewolf Therapeutics cuts 64% of workforce; CFO and CMO resign](https://aibio.space/news/werewolf-therapeutics-cuts-64-percent-workforce-cfo-cmo-resign/)

Werewolf expects a one-time charge of approximately $4.1 million in the first quarter of 2026. The filing also discloses the company's efforts to raise capital and a review of strategic partnerships for WTX-124 and WTX-330.

## Latest Werewolf Therapeutics news

1. 2025-10-06 Listings [Werewolf Therapeutics breaks Nasdaq audit committee rule after director dies](https://aibio.space/news/werewolf-therapeutics-breaks-nasdaq-audit-committee-rule-after/) The death of director Dr. Alon Lazarus on September 30, 2025 left Werewolf's audit committee with two members, one short of Nasdaq's three-member minimum. The company plans to appoint an independent director at its earliest opportunity.

## Werewolf Therapeutics at a glance

- **Ticker**: HOWL

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $22.0 million

### Related companies

- [Aoxing Pharmaceutical Company](https://aibio.space/companies/aoxing-pharmaceutical/) OTC: AOXG
- [Coherus Oncology](https://aibio.space/companies/coherus-oncology/) NASDAQ: CHRS
- [AEON Biopharma](https://aibio.space/companies/aeon-biopharma/) AMEX: AEON
- [Northwest Biotherapeutics](https://aibio.space/companies/northwest-biotherapeutics/) OTC: NWBO
- [Veradermics](https://aibio.space/companies/veradermics/) NYSE: MANE
- [Puma Biotechnology](https://aibio.space/companies/puma-biotechnology/) NASDAQ: PBYI
- [Latigo Biotherapeutics](https://aibio.space/companies/latigo-biotherapeutics/) NASDAQ: LTGO
- [Regeneron Pharmaceuticals](https://aibio.space/companies/regeneron-pharmaceuticals/) NASDAQ: REGN

### Also on NASDAQ

- [Cardio Diagnostics Holdings](https://aibio.space/companies/cardio-diagnostics/) CDIO
- [Iovance Biotherapeutics](https://aibio.space/companies/iovance-biotherapeutics/) IOVA
- [Q32 Bio](https://aibio.space/companies/q32-bio/) QTTB
- [Korro Bio](https://aibio.space/companies/korro-bio/) KRRO
- [Alkermes](https://aibio.space/companies/alkermes/) ALKS
- [Arbutus Biopharma](https://aibio.space/companies/arbutus-biopharma/) ABUS

## Werewolf Therapeutics annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$0](https://www.sec.gov/Archives/edgar/data/1785530/000178553026000006/) | [$1.9 million](https://www.sec.gov/Archives/edgar/data/1785530/000178553026000006/) |
| Research and development | [$44.8 million](https://www.sec.gov/Archives/edgar/data/1785530/000178553026000006/) | [$56.4 million](https://www.sec.gov/Archives/edgar/data/1785530/000178553026000006/) |
| Net income (loss) | [-$60.8 million](https://www.sec.gov/Archives/edgar/data/1785530/000178553026000006/) | [-$70.5 million](https://www.sec.gov/Archives/edgar/data/1785530/000178553026000006/) |
| Cash from operations | [-$60.3 million](https://www.sec.gov/Archives/edgar/data/1785530/000178553026000006/) | [-$56.2 million](https://www.sec.gov/Archives/edgar/data/1785530/000178553026000006/) |
| Cash and equivalents | [$57.0 million](https://www.sec.gov/Archives/edgar/data/1785530/000178553026000019/) | [$111.0 million](https://www.sec.gov/Archives/edgar/data/1785530/000178553026000006/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $22.0 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Werewolf Therapeutics

What is the ticker symbol of Werewolf Therapeutics?

Werewolf Therapeutics, Inc. trades under the ticker HOWL on NASDAQ.

Where is Werewolf Therapeutics listed?

Werewolf Therapeutics, Inc. is listed on NASDAQ.

What is the SEC CIK of Werewolf Therapeutics?

The SEC Central Index Key (CIK) for Werewolf Therapeutics, Inc. is 1785530. Its filings are on SEC EDGAR.

How many shares does Werewolf Therapeutics have outstanding?

48,599,066 shares as of 2026-07-27, per the cover page of its 10-Q filed 2026-07-31.

Which country or territory is Werewolf Therapeutics listed under?

Our directory records Werewolf Therapeutics, Inc. under United States.

What does Werewolf Therapeutics do?

Our directory classifies Werewolf Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Werewolf Therapeutics?

The ISIN recorded for Werewolf Therapeutics, Inc. is US95075A1079.

Does aibio.space cover Werewolf Therapeutics?

aibio.space lists Werewolf Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Werewolf Therapeutics incorporated?

SEC records list its state or country of incorporation as DE.

What was Werewolf Therapeutics's revenue last year?

$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is Werewolf Therapeutics profitable?

Werewolf Therapeutics, Inc. reported a net loss of $60.8 million for the fiscal year ended Dec 31, 2025, and used $60.3 million of cash in operations, per its annual report to the SEC.

How much does Werewolf Therapeutics spend on research and development?

$44.8 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Werewolf Therapeutics have?

$22.0 million in cash at Jun 30, 2026, per its 10-Q.

What is the latest Werewolf Therapeutics (HOWL) stock news?

Our latest story on Werewolf Therapeutics, dated Feb 13, 2026: "Werewolf Therapeutics cuts 64% of workforce; CFO and CMO resign". Werewolf expects a one-time charge of approximately $4.1 million in the first quarter of 2026. The filing also discloses the company's efforts to raise capital and a review of strategic partnerships for WTX-124 and WTX-330. [Source](https://aibio.space/news/werewolf-therapeutics-cuts-64-percent-workforce-cfo-cmo-resign/).

Is Werewolf Therapeutics in financial distress?

Our latest distress story, dated Feb 13, 2026: "Werewolf Therapeutics cuts 64% of workforce; CFO and CMO resign". Werewolf expects a one-time charge of approximately $4.1 million in the first quarter of 2026. The filing also discloses the company's efforts to raise capital and a review of strategic partnerships for WTX-124 and WTX-330. [Source](https://aibio.space/news/werewolf-therapeutics-cuts-64-percent-workforce-cfo-cmo-resign/).

## Investor discussion: Werewolf Therapeutics

Members talk about Werewolf Therapeutics (HOWL). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Werewolf Therapeutics, newest first. Each line links the filing it comes from.

1. 2026-08-21 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1785530/000119312526360059/d102535dex991.htm)
2. 2026-02-24 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1785530/000119312526067569/d808115dex991.htm)
3. 2026-02-13 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02,7.01). [Source](https://www.sec.gov/Archives/edgar/data/1785530/000119312526051455/d110809d8k.htm)
4. 2026-02-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1785530/000119312526041305/d101154d8k.htm)
5. 2025-11-04 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1785530/000178553025000031/howl-20250930.htm)
6. 2025-10-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1785530/000119312525231953/d12663d8k.htm)
7. 2025-05-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1785530/000119312525120910/d938755d8k.htm)
8. 2025-03-11 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1785530/000119312525051439/d923811d424b5.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:HOWL on TradingView](https://www.tradingview.com/symbols/NASDAQ-HOWL/).

## SEC filings and registration

- **SEC name**: Werewolf Therapeutics, Inc.

- **CIK**: 1785530

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: HOWL (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

- **Business address**: 303 WYMAN STREET, WALTHAM, MA, 02451

- **Phone**: 617-952-0555

- **Shares outstanding**: 48,599,066 as of 2026-07-27 (10-Q filed 2026-07-31)

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1785530/000119312526360059/d102535d8k.htm) filed 2026-08-21
- [8-K](https://www.sec.gov/Archives/edgar/data/1785530/000119312526359185/d141219d8k.htm) filed 2026-08-20
- [10-Q](https://www.sec.gov/Archives/edgar/data/1785530/000178553026000019/howl-20260630.htm) filed 2026-07-31
- [8-K](https://www.sec.gov/Archives/edgar/data/1785530/000178553026000018/howl-20260731.htm) filed 2026-07-31
- [10-Q](https://www.sec.gov/Archives/edgar/data/1785530/000178553026000012/howl-20260331.htm) filed 2026-05-07
- [8-K](https://www.sec.gov/Archives/edgar/data/1785530/000178553026000011/howl-20260507.htm) filed 2026-05-07
- [10-K](https://www.sec.gov/Archives/edgar/data/1785530/000178553026000006/howl-20251231.htm) filed 2026-03-27
- [8-K](https://www.sec.gov/Archives/edgar/data/1785530/000178553026000005/howl-20260327.htm) filed 2026-03-27

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001785530), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Werewolf Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker HOWL, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Werewolf Therapeutics, Inc.

- **Ticker**: HOWL

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US95075A1079

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-HOWL/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/werewolf-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Werewolf Therapeutics (HOWL) stock and investor profile", 2026-10-31, https://aibio.space/companies/werewolf-therapeutics/